SIDE EFFECTS

A079 - REAL-WORLD CLINICAL FEATURES OF NEUROTOXICITY COMPLICATING CD19-TARGETED CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY FOR HIGH GRADE LYMPHOMA AND MANAGEMENT INCLUDING THE OFF-LABEL USE OF ANAKINRA

Shafqat Inam, Sean Apap Mangion, Victoria Potter, et al.

Conclusions: We describe the clinical features of ICANS in our real-world cohort of patients receiving standard of care CD19 CAR T-cells, and demonstrate the feasibility of anakinra in combination with dexamethasone for treatment ICANS that is severe or not initially responsive to high dose steroids.

A082 - ASSOCIATION OF AXI-CEL CAR-T CELL CONCENTRATION WITH TREATMENT RESPONSE AND SIDE EFFECTS AND IMPACT OF DEXAMETHASONE TREATMENT ON KINETICS

Francis Ayuk, Anita Badbaran, Carolina Berger, et al.

Conclusions: Despite the relatively small patient number, our data emphasize the importance of monitoring CAR-T concentrations after infusion and indicate an association with response and side effects. CAR-T cell proliferation appears to bounce back after treatment with dexamethasone.

A101 - EMERGING CYTOKINE RELEASE SYNDROME IS ASSOCIATED WITH REDUCTION OF CD4+CD25HIGH127DIM T REGULATORY CELLS IN PATIENTS AFTER CAR T CELL THERAPY

Christian R Schultze-Florey, Victoria Panagiota, Ivan Odak, et al.

Conclusions: In this prospective single center pilot study, blood samples of emerging CRS showed a reduction of Tregs frequencies and absolute numbers compared to no-CRS patients. After clearance of CRS, Tregs frequencies increased to values of no-CRS patients. Therefore, investigation of Treg frequencies as a predictive marker for CRS should be further investigated. However, future studies are needed to validate these findings in a larger cohort.

A112 - NEUROTOXICITY ASSOCIATED WITH CAR T CELL THERAPY: NEUROLOGICAL MANAGEMENT AND WORK-UP OF 11 ADULT PATIENTS

Nora Moehn, Viktoria Bonda, Mike P. Wattjes, et al.

Conclusions: Neurotoxicity is a feared complication of CD19 CAR T cell therapy and initial symptoms can be very subtle. Our longitudinal examinations in 11 patients revealed specific clinical symptoms of ICANS in 2 patients without relevant radiological abnormalities. Further studies with higher numbers of patients including a structured and detailed neurological examination are required to uncover CD19 CAR T cell-related neurotoxicity and its especially pathogenesis.